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Endothelial nitric-oxide synthase (eNOS), the enzyme
responsible for production of endothelial NO, is under
tight and complex regulation. Proper cellular localiza-
tion of eNOS is critical for optimal coupling of extracel-
lular stimulation with NO production. In addition, the
molecular chaperone Hsp90 interacts with eNOS and
positively regulates eNOS activity. Hsp90 is modulated
by physical interaction with its co-chaperones. CHIP
(carboxyl terminus of Hsp70-interacting protein) is such
a co-chaperone that remodels the Hsp90 heterocomplex
and causes protein degradation of some Hsp90 sub-
strates through the ubiquitin-protein isopeptide ligase
activity of CHIP. Here we show that CHIP incorporated
into the eNOSHsp90 complex and specifically decreased
soluble eNOS levels in transiently transfected COS cells.
Surprisingly, in contrast to the effects of the Hsp90 in-
hibitor geldanamycin, which induces eNOS ubiquityla-
tion and its subsequent protein degradation, CHIP did
not target eNOS for ubiquitylation and proteasome-de-
pendent degradation. Instead, CHIP partitioned soluble
eNOS into an insoluble and inactive cellular compart-
ment, presumably through its co-chaperone activity.
This effect seems to be due to displacement of eNOS
from the Golgi apparatus, which is otherwise required
for trafficking of eNOS to the plasmalemma and subse-
quent activation. Consistent with observations from
overexpression studies, eNOS localization to the mem-
brane and activity were increased in mouse lung endo-
thelial cells lacking CHIP. Taken together, these results
demonstrate a novel co-chaperone-dependent mecha-
nism through which eNOS trafficking is regulated and
suggest a potentially generalized role for CHIP in pro-
tein trafficking through the Golgi compartment.
The nitric-oxide synthases (NOSs)1 are a family of mamma-
lian enzymes that catalyze the oxidation of L-arginine to pro-
duce NO and L-citrulline. Three NOS isoforms exist in mam-
malian cells, neuronal (nNOS; NOS1), inducible (iNOS; NOS2),
and endothelial (eNOS; NOS3), named after the cell types in
which they were originally discovered. All NOS isoforms have
similar primary structures, including an oxygenase domain at
the N terminus, a reductase domain at the C terminus, and a
hinge calmodulin domain in between. eNOS is unique among
the NOS isoforms in that it is dually acylated by myristate and
palmitate. Cysteine palmitoylation is necessary for targeting of
eNOS to the specific plasmalemmal microdomain, caveolae (1),
and both fatty acylations are required for specific targeting of
eNOS to the Golgi (2). Correct subcellular trafficking and lo-
calization to the plasmalemma is necessary for eNOS function.
eNOS produces NO (and/or other reactive nitrogen species) in
vascular endothelial cells and cardiomyocytes in response to a
variety of agonists and mechanical stimuli (i.e. shear) (3, 4).
Mislocalization of the enzyme to either domain impairs ago-
nist-stimulated eNOS activation and optimal NO release from
cells, implying that the proper subcellular localization of eNOS
is critical for optimal coupling of extracellular stimulation with
nitric oxide production (5, 6).
The 90-kDa heat shock proteins (Hsp90) are one of the most
abundant proteins in cells, accounting for 1–2% of cytosolic
protein. Hsp90 is a ubiquitous molecular chaperone with es-
sential roles in stress tolerance and protein folding. Most of its
known substrates are signaling proteins, including steroid re-
ceptors, some transcription factors (aryl hydrocarbon receptor,
Sim, MyoD1, etc.), and a variety of tyrosine kinases (ErbB-2,
Src, insulin receptor, focal adhesion kinase, etc.) and serine/
threonine kinases (Raf, Cdk4, MEK (mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase), etc.) (re-
viewed in Ref. 7). eNOS has recently been recognized as an-
other Hsp90 client (3). Hsp90 is physically associated with
eNOS in resting endothelial cells. Activation of endothelial
cells by vascular endothelial growth factor, histamine, fluid
shear stress, and estrogen enhances the interaction between
eNOS and Hsp90 and increases eNOS activity. The mechanism
of this activation is presently unclear. Hsp90 may act as an
allosteric activator of eNOS (3) and/or as a scaffold of eNOS and
the serine/threonine kinase Akt (8), the recruitment of which to
the eNOSHsp90 complex leads to eNOS phosphorylation and
activation (9, 10). There are also studies suggesting that Hsp90
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may couple eNOS oxidation (11) or facilitate the replacement of
caveolin by calmodulin as a binding partner for eNOS (12).
nNOS is an Hsp90 client as well. Hsp90 associates with nNOS
and chaperones its maturation (13, 14). Whether similar effects
are involved in eNOS regulation remains to be determined,
although both proteins have similar structure.
In vivo, Hsp90 is not functional unless associated in hetero-
complexes with a range of accessory proteins. The tetratri-
copeptide repeat (TPR)-containing proteins are one major
group of Hsp90 partner proteins. Various TPR proteins com-
pete for binding to a TPR acceptor site at the C terminus of
Hsp90 and thus regulate the chaperone function of Hsp90.
CHIP (carboxyl terminus of Hsp70-interacting protein) is a
recently identified Hsp90 cofactor (15). CHIP interacts with
Hsp90 through its N-terminal TPR domain and stimulates
protein degradation of the following Hsp90 substrates: the
glucocorticoid receptor (GR), the cystic fibrosis transmembrane
conductance receptor (CFTR), and ErbB-2 (15–18). Moreover,
CHIP-induced protein degradation is not simply a consequence
of interference with chaperone function, as is thought to be the
case for the Hsp90 inhibitor geldanamycin (GA). CHIP contains
a U-box domain at its C terminus and directly targets diverse
chaperone substrates to the ubiquitin-proteasome system
through its ubiquitin-protein isopeptide ligase (E3) activity
(18–20). In this way, CHIP shifts the balance from protein
folding to protein degradation during protein quality control,
although, at the present time, the range of substrates for CHIP
ubiquitination activity is not known.
Although CHIP is a ubiquitous protein, its high level expres-
sion in heart and endothelial cells (21) suggests that CHIP may
interact with proteins that play important roles in cardiovas-
cular function. In this study, we sought to determine whether
the effects of CHIP on Hsp90 substrates such as GR and
ErbB-2 could be generalized to the Hsp90 substrate eNOS in
consideration of eNOS modulation by Hsp90 and its significant
role in the cardiovascular system. Instead, we found that CHIP
elicited partitioning of eNOS to the insoluble compartment and
impaired trafficking through the Golgi apparatus, indicating a
novel chaperone-dependent mechanism for regulation of eNOS
activity.
EXPERIMENTAL PROCEDURES
Cell Culture—COS-7 cells were obtained from American Type Cul-
ture Collection and were cultured in Dulbecco’s modified Eagle’s me-
dium supplemented with 10% fetal bovine serum. COS-7 cells were
transiently transfected using FuGENE (Roche Applied Science) as de-
scribed previously (19). Bovine aortic endothelial cells were harvested
and cultured as described previously (22). Recombinant adenoviruses
were constructed with the Ad-Easy system, and cultures were routinely
infected at a multiplicity of infection of 5. Western blotting and indirect
immunofluorescence were performed as described previously (15).
Mouse lung endothelial cells were isolated from CHIP/ or wild-type
mice.2 Lungs from mice were finely minced and incubated in 0.1%
collagenase for 1 h at 37 °C. Cells were further homogenized by passage
through a 14-guage needle and sieved to remove undigested material.
Isolated cells were washed and then incubated with rat anti-mouse
ICAM-2 (intercellular adhesion molecule-2) antibody coupled to mag-
netic beads (Dynabeads M-450, Dynal, Inc.). After magnetic selection,
cells were plated in tissue culture flasks and cultured as described
previously (22). The endothelial phenotype of isolated cells was con-
firmed by staining for PECAM (platelet/endothelial cell adhesion
molecule).
Antibodies and Chemicals—The following antibodies were used for
immunoblotting: mouse anti-eNOS (clone H32; BIOMOL Research
Labs Inc.), mouse anti-iNOS and rabbit anti-nNOS (Transduction Lab-
oratories), mouse anti-ubiquitin (Babco), mouse anti-Hsp90 and mouse
anti-Hsc/Hsp70 (Stressgen Biotech Corp.), mouse anti--actin (Santa
Cruz Biotechnology), and rabbit anti-CHIP (21). Mouse anti-Hsp90
(3G3), mouse anti-eNOS, and mouse anti-Myc antibody-agarose conju-
gates (Santa Cruz Biotechnology) were used for immunoprecipitation.
GA was purchased from Calbiochem and used at 2 M. The proteasome
inhibitors MG132, lactacystin, and proteasome inhibitor I were pur-
chased from Calbiochem and used as indicated. nickel-nitrilotriacetic
acid (Ni-NTA)-agarose was from QIAGEN Inc.
Western Blotting and Immunoprecipitation—Transfected COS cells
were harvested 36–48 h after transfection and lysed with modified
radioimmune precipitation assay buffer (100 mM Tris (pH 7.4), 1%
Nonidet P-40, 10 mM NaF, and 1 mM Na3VO4) (23) supplemented with
protease inhibitors and 50 mM N-ethylmaleimide to inhibit ubiquitin-
cleaving isopeptidase. Cell lysates were clarified by centrifugation at
16,000  g for 10 min at 4 °C, and protein concentration was deter-
mined with a protein assay kit (Bio-Rad). In some experiments, proteins
in the pellets were recovered by resuspension of pellets in the lysis
buffer and sonication. Immunoprecipitation was performed as de-
scribed previously (19). For some immunoprecipitations, 20 mM sodium
molybdate was added in the lysis buffer to stabilize the interaction
between Hsp90 and its substrate eNOS. Immunoprecipitated proteins
or cell lysates were mixed with SDS sample buffer and separated by
SDS-PAGE.
RNA Isolation and Northern Blot Analysis—Total RNA (2 g) was
prepared as described previously (21). eNOS and 18 S cDNAs were
labeled with 32P by random priming and used to hybridize filters.
Filters were autoradiographed.
In Vitro Ubiquitylation Reactions—Bacterially expressed eNOS (0.25
g) was incubated in reactions containing 0.1 M purified rabbit ubiq-
uitin-activating enzyme (E1) (Calbiochem), 8 M UBCH5a, 4 M CHIP,
2.5 mg/ml ubiquitin (Sigma), and 5 mM ATP in 20 mM MOPS (pH 7.2),
100 mM KCl, 5 mM MgCl2, 10 mM dithiothreitol, and 1 mM phenylmeth-
ylsulfonyl fluoride for 2 h at 30 °C. In some reactions, 2 M Hsp70 and
4 M Hdj1 or Hdj2 were included. Reactions were stopped with SDS
loading buffer, subjected to SDS-PAGE, and then immunoblotted with
appropriate antibodies. For ubiquitylation of in vitro translated eNOS,
eNOS was transcribed and translated with the TNT coupled reticulocyte
lysate system (Promega). Following translation, 35S-labeled eNOS was
immunoprecipitated with mouse anti-eNOS antibody, and the immu-
nocomplex was immobilized on anti-mouse IgG-agarose conjugate. The
washed immobilized complex was used as a substrate in ubiquitin
conjugation reactions. Reactions were stopped with SDS loading buffer,
separated by SDS-PAGE, and autoradiographed.
Ni-NTA-Agarose Conjugate Pull-down Assay—His-tagged proteins
were precipitated following a previously described method (24) as mod-
ified. Briefly, 45 h after transfection, COS cells were treated with 2.5 M
MG132 for 2.5 h and lysed in 1 ml of buffer A (6 M guanidinium chloride,
0.1 M Na2HPO4/NaH2PO4 (pH 8.0), and 10 mM imidazole)/100-mm dish.
Lysates were passed through a 26-gauge needle to reduce viscosity and
then mixed on a rotator with 15 l (settled volume) of Ni-NTA-agarose/
250 g of lysates for 2 h at room temperature. The beads were washed
three times with 1 ml of buffer A, twice with 1 ml of buffer A diluted in
25 mM Tris-HCl (pH 6.8) and 20 mM imidazole (1:4), and twice with 1 ml
of 25 mM Tris-HCl (pH 6.8) and 20 mM imidazole. His-tagged proteins
were eluted by boiling beads in 1 SDS sample buffer supplemented
with 100 mM EDTA and then analyzed by immunoblotting.
Cellular Fractionation—Transfected or primary culture cells were
lysed in Tris/Triton extraction buffer (100 mM Tris-HCl (pH 7.4), 2%
Triton X-100, 1 mM Na3VO4, 0.5 mM phenylmethylsulfonyl fluoride,
protease inhibitors, and 10 mM EGTA (pH 8.0)) (25, 26), and the cy-
toskeleton was pelleted by centrifugation at 15,000  g for 5 min. The
supernatant from this low speed centrifugation was centrifuged at
100,000  g for 5 h at 4 °C in a Beckman SW 60 Ti rotor. The super-
natant from this centrifugation was considered the cytosol, and the
insoluble pellet was considered the membrane fraction. The pellet was
resuspended in 100 l of Tris/Triton extraction buffer and sonicated
until fully dissolved. Fractions were resuspended in SDS sample buffer,
and immunoblot analysis was performed.
NOS Activity Assay—NOS activity from transiently transfected COS
cell lysates or mouse lung endothelial cells was measured by the con-
version of L-[3H]arginine to L-[3H]citrulline with the NOS activity kit
from Calbiochem-Novabiochem. Briefly, COS cells were transfected
as described above and harvested 48 h after transfection. The cells
were homogenized in homogenization buffer (25 mM Tris-HCl (pH
7.4), 1 mM EDTA, and 1 mM EGTA) supplemented with protease inhib-
itors and pelleted at 16,000  g for 2 min at 4 °C. Both supernatant and
pellets were used for eNOS activity determinations (25–50 g of
protein/reaction).
Statistical Analysis—Data were analyzed using a one-way analysis
of variance, followed by an unpaired Student’s t test.2 Q. Dai and C. Patterson, submitted for publication.
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RESULTS
Detergent-soluble eNOS Protein Levels Are Decreased by
CHIP in Transfected COS Cells—To test the hypothesis that
CHIP regulates eNOS through an Hsp90-dependent mecha-
nism, we first examined whether CHIP has effects on eNOS
expression in COS cells. COS cells are a good system for this
purpose because previous studies have shown that exogenously
expressed eNOS in COS cells behaves similarly to endogenous
eNOS with respect to intracellular trafficking and activation
(3). COS cells (which do not express NOS) were cotransfected
with eNOS and CHIP, and the expression of eNOS protein was
measured by Western blotting. Detergent-soluble eNOS levels
in both cell lysates and immunoprecipitates were markedly
reduced in cells overexpressing CHIP (Fig. 1A), whereas eNOS
mRNA expression was not altered (Fig. 1B). The effects of
CHIP were dose-dependent; with increasing amounts of CHIP,
eNOS levels decreased further (Fig. 1C).
Kinetics of Detergent-soluble eNOS Stability Is Altered by
CHIP—Having shown previously that CHIP targets chaperone
substrates for ubiquitylation and rapid degradation in vivo (15,
16, 18), we examined whether the stability of eNOS is altered
in the presence of increased levels of CHIP using pulse-chase
experiments. We cotransfected eNOS with or without CHIP,
pulse-labeled the cells with [35S]methionine, and harvested at
different time points. The detergent-soluble fraction of the ly-
sate was immunoprecipitated with an antibody recognizing
eNOS. At time 0, similar levels of eNOS were present in control
cells and in cells that overexpressed CHIP. An increased rate of
eNOS disappearance was observed in cells that overexpressed
CHIP (Fig. 1D), suggesting either that CHIP induced an accel-
erated rate of eNOS degradation or that CHIP caused eNOS
redistribution into a detergent-insoluble pool.
Effect of CHIP on eNOS Expression Is Hsp90-dependent—To
determine whether CHIP elicits its effect through Hsp90-de-
pendent mechanisms, we overexpressed Hsp90 in transfected
cells. These studies were designed to test whether an increase
in the cellular ratio of Hsp90 to CHIP would be able to rescue
eNOS expression, as should be the case if this event is medi-
ated through interactions between CHIP and eNOSHsp90
complexes. Cotransfection of Hsp90 with CHIP blocked the
ability of CHIP to decrease eNOS levels in a dose-dependent
manner (Fig. 1B). In addition, we compared the effects of CHIP
FIG. 1. Detergent-soluble eNOS pro-
tein levels are decreased by CHIP. A,
COS-7 cells were transiently transfected
with eNOS with or without CHIP expres-
sion plasmids as indicated. Detergent-sol-
uble fractions of lysate and eNOS immu-
noprecipitations (IP) were subjected to
Western blotting with anti-eNOS anti-
body. B, COS-7 cells were transfected as
described for A, and Northern blots were
probed with a [32P]dCTP-labeled eNOS
probe. C, COS-7 cells were transiently
transfected with eNOS and different
amounts of CHIP plasmids with or with-
out Hsp90 as indicated. Detergent-soluble
fractions of lysates were immunoblotted
for eNOS (upper panel) and CHIP (lower
panel). D, COS-7 cells transfected with
eNOS with or without CHIP were meta-
bolically labeled with 50 Ci/ml [35S]me-
thionine for 20 min and chased at differ-
ent time points as indicated. eNOS was
immunoprecipitated from the detergent-
soluble fraction of lysate and identified by
SDS-PAGE, followed by autoradiography.
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with those of GA, a specific inhibitor of Hsp90, on eNOS levels.
Both CHIP and GA caused similar decreases in eNOS protein
levels (Fig. 2A), whereas CHIP increased nNOS levels and GA
decreased nNOS levels (Fig. 2B). Having shown previously that
CHIP interacts with the TPR acceptor site of Hsp90 through
the CHIP N-terminal TPR domain (15), we examined the re-
quirement of this domain for CHIP action. Deletion of the TPR
domain (TPR) markedly reduced the effects of CHIP on eNOS
(Fig. 3, left panel), suggesting that the effects of CHIP are TPR
domain- and most likely Hsp90-dependent. Several lines of
evidence suggested to us that decreased eNOS expression by
CHIP is likely mediated through its inhibition of Hsp90 func-
tion: 1) increasing Hsp90 overcomes the effect of CHIP, and 2)
CHIP action is dependent on its ability to interact with Hsp90
(i.e. it is TPR domain-dependent).
To test the specificity of this effect, we examined the activity
of CHIP on other NOS isoforms. The effects of CHIP on soluble
eNOS and iNOS levels were similar (Fig. 3). In contrast, we
noticed a consistent increase in nNOS protein levels in cells
overexpressing CHIP (Fig. 3, right panel), the consequence and
mechanisms of which are unclear at present. We found as well
that endogenous -actin expression was unaffected by CHIP
(Fig. 3). Together, these data demonstrate a surprising speci-
ficity of the effects of CHIP on NOS isoforms. We therefore
explored the mechanisms underlying the effects of CHIP on
steady-state eNOS levels in more detail.
CHIP Interacts with eNOS and Hsp90—Previous studies
have shown that Hsp90 interacts with eNOS and activates
eNOS activity (3). If CHIP directly modulates eNOS expression
through the chaperone activity of Hsp90, then we should be
able to detect stable interactions between CHIP and eNOS. We
examined interactions between these proteins by co-immuno-
precipitation in COS cells cotransfected with Myc-tagged CHIP
(which enabled us to measure only ectopically expressed CHIP)
and eNOS and harvested cells with a buffer containing molyb-
date (which mimics nucleotide binding and stabilizes the asso-
ciation of Hsp90 and its client proteins (27)). Although eNOS
levels were decreased in CHIP-expressing cells, CHIP was still
present in a stable complex with eNOS and Hsp90 (Fig. 4, A
and B). These data indicate the likely formation of a ternary
complex containing these three proteins. Binding domains of
eNOS and Hsp90 have recently been mapped to the oxygenase
domain of eNOS and the M domain of Hsp90 (which is far away
from the C-terminal CHIP-binding site) (8). To further charac-
terize the spatial arrangement among these three proteins, we
conducted the same experiment with a molybdate-free buffer.
Association of Hsp90 and its substrate eNOS could not be
detected with the molybdate-free buffer. Although the interac-
tion between eNOS and CHIP was abrogated, Hsp90 could still
bind CHIP (Fig. 4C). These results indicate that the association
of CHIP and eNOS is probably not direct, but is instead medi-
ated by Hsp90 (Fig. 4D).
eNOS Is Not a Target for CHIP-mediated Ubiquitylation—
CHIP is a U-box-dependent E3 ligase (18–20) that directly
participates in the ubiquitylation of chaperone substrates such
as GR, CFTR, and ErbB-2 and their transfer to the proteasome
for degradation (15–17). Ubiquitylation of GR and CFTR can be
recapitulated by an in vitro reconstitution reaction with puri-
fied components of the ubiquitin system. In addition to the
TPR mutant, we noted that a deletion mutant lacking the
U-box domain (U), a domain first identified in the yeast pro-
tein Ufd2 and known to facilitate protein polyubiquitylation
(28), also inhibited the effects of CHIP on eNOS expression
(Fig. 3, left panel). To determine whether CHIP modulates eNOS
expression through mechanisms similar to those observed with
GR and CFTR, we tested the ability of CHIP to elicit ubiquityla-
tion of eNOS in an in vitro ubiquitin conjugation system. Reac-
tions were carried out with recombinant proteins, including rab-
bit E1, UBCH5a (a collaborating ubiquitin-conjugating enzyme
for CHIP) (19), and CHIP; and the capacity of these components
to mediate ubiquitylation of bacterially expressed eNOS in the
presence of purified ubiquitin and ATP was examined. We found
that CHIP did not increase ubiquitylated high molecular mass
forms of eNOS in the presence of E1, ubiquitin carrier protein
(E2), and ubiquitin (Fig. 5A, first and second lanes).
The requirement of chaperones for ubiquitylation of some
chaperone substrates has been reported (29, 30). To test
whether this is the reason why we failed to detect ubiquityla-
tion of eNOS, recombinant Hsp70 was included in the reactions
with or without its co-chaperone Hdj1 or Hdj2, the mammalian
Hsp40 homologs. In contrast to the observation of CHIP-medi-
ated Hsp70 ubiquitylation, no obvious increase in eNOS ubiq-
uitylation was observed in the same reaction (Fig. 5A, third
through fifth lanes), although these conditions efficiently in-
creased the ubiquitylation of other CHIP substrates (data not
shown). Because the above reactions did not include Hsp90, we
used eNOS generated in reticulocyte lysate (which has suffi-
cient quantities of Hsp90 heterocomplex components (31)) as a
source of substrate to test the ability of CHIP to ubiquitylate
eNOS. With an approach similar to that used for characterizing
CHIP-mediated ubiquitylation of GR (15), we incubated eNOS
with CHIP and ubiquitin after its in vitro transcription and
FIG. 2. Differential effects of CHIP and GA on NOS isoforms. COS-7 cells were transfected with eNOS (A) or nNOS (B) with or without
CHIP or pretreatment with 2 M GA for 16 h. Detergent-soluble lysates were immunoblotted for the respective NOS proteins and for endogenously
expressed -actin.
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translation of eNOS in reticulocyte lysate (which contains he-
min to inhibit the proteasome). Low levels of eNOS ubiquity-
lation were observed after translation; but again, we did not
observe any augmentation with CHIP (Fig. 5B).
We utilized an established assay for the detection of ubiqui-
tylated proteins (32) to further examine whether CHIP ubiqui-
tylates eNOS in vivo. COS cells were transfected with eNOS
plus His6- or hemagglutinin-tagged ubiquitin (serving as a
control) with or without CHIP. Cell extracts were prepared
under denaturing conditions (6 M guanidinium chloride) and
purified on Ni-NTA beads. Ubiquitylated proteins represent
intermediates of degradation and are thus both rare and labile.
Denaturing conditions were used to prevent degradation or
de-ubiquitylation of protein-ubiquitin conjugates as well as any
noncovalent protein-protein interactions. Because the interac-
tion of His6 sequences with the NTA affinity resin is not im-
peded by the presence of guanidinium chloride, tagged ubiq-
uitin and its modified derivatives could be directly purified
from the lysates by NTA chromatography. Treating cells with
GA increased eNOS ubiquitylation in the presence of a protea-
some inhibitor (Fig. 5C, sixth lane). However, contrary to our
expectation, we found no increase (in fact, a decrease) in ubiq-
uitin-modified forms of eNOS by CHIP under the same condi-
tions (fifth lane), although reprobing the same blot with ubiq-
uitin revealed an increase in overall ubiquitylated forms of
proteins in cells overexpressing CHIP (which is consistent with
our previous observations (19)) (Fig. 5C). We observed similar
results in COS cells overexpressing Myc-tagged ubiquitin, har-
vested with nondenaturing buffer, and detected by immunopre-
cipitation (data not shown).
Proteasome-dependent Protein Degradation Is Not Required
for Regulation of eNOS by CHIP—CHIP promotes the protea-
FIG. 3. Effects of CHIP require both the TPR and U-box domains of CHIP, and CHIP shows different effects on different NOS
isoforms. COS-7 cells were transfected with eNOS (left panels), iNOS (middle panels), or nNOS (right panels) expression plasmids with or without
the wild type or deletion mutants lacking the TPR (residues 1–145; TPR) or U-box (residues 196–303; U) domain of CHIP. Western blots (WB)
were probed with antibodies to the respective NOSs (upper panels), to CHIP (middle panels), or to endogenously expressed -actin (lower panels).
FIG. 4. Formation of a ternary CHIPeNOSHsp90 complex. COS-7 cells were transfected with eNOS with or without Myc-tagged CHIP (A)
or non-tagged CHIP (B). Detergent-soluble lysates were immunoprecipitated (IP) with anti-Myc, anti-Hsp90, or anti-eNOS antibody and blotted
for eNOS, Hsp90, and CHIP, respectively. In C, COS-7 cells were transfected and immunoprecipitated as described for B, except that lysates were
harvested in a molybdate-free buffer. A putative model of the ternary complex is shown in D. Hsp90 scaffolds the interaction between eNOS and
CHIP. NS, nonspecific. M, middle.
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some-dependent degradation of chaperone substrates such as
GR and CFTR (15, 16, 18). To determine whether this mecha-
nism could be generalized to the Hsp90 substrate eNOS, we
examined the requirement of the proteasome pathway for
CHIP actions on eNOS. Because it is well accepted that pro-
teasome inhibitors block proteasome-mediated proteolysis and
that they lead to an accumulation of proteins metabolized by
this pathway, we utilized selective proteasome inhibitors to
test this hypothesis. Proteasome inhibitors should be able to
restore eNOS expression decreased by CHIP if the proteasome
pathway is involved. Treating transfected COS cells with the
proteasome inhibitors lactacystin, MG132, and proteasome in-
hibitor I for 2.5 h did not result in restoration of eNOS expres-
sion in cells cotransfected with CHIP, even though a slowly
migrating smear of high molecular mass ubiquitylated proteins
was more abundant in treated cells (indicating that the inhib-
itors were functional) (Fig. 6A). Because eNOS has a relatively
long half-life of 15–20 h (33), it is possible that this treatment
(2.5 h) was not long enough. We therefore treated cells for a
longer time; but again, a 12-h treatment did not rescue the
effect of CHIP on eNOS expression (Fig. 6B). In addition, in-
hibitors of the other two major cellular protein degradation
systems, the lysosome and calcium-dependent calpain pro-
teases, were tested, and neither of these blocked the effects of
CHIP on eNOS (data not shown). Our results indicate that the
degradation of eNOS does not account for the effects of CHIP
observed in our preceding studies.
Taken together, multiple lines of evidence demonstrate that,
although disruption of Hsp90 function by GA induces eNOS
ubiquitylation, the Hsp90-interacting CHIP is not the E3 ligase
responsible for this event, indicating that other chaperone-
associated E3 ligases exist and are responsible for eNOS ubiq-
uitylation. In addition, the effects of CHIP on eNOS do not
involve ubiquitin-dependent degradation, suggesting that
CHIP has previously unsuspected effects on protein trafficking
and maturation.
CHIP Alters Compartmental Partitioning of eNOS—The
aforementioned results do not support our initial hypothesis
that CHIP inhibits eNOS maturation and promotes eNOS deg-
radation via the ubiquitin-proteasome system. CHIP is a co-
chaperone of Hsp70 that inhibits most of the chaperoning ac-
tivities of Hsp70 (including refolding activity) (21). In addition,
CHIP interacts with Hsp90 and prevents the assembly of an
Hsp90 chaperone complex required for protein folding and mat-
uration (15). Based on this knowledge, we proposed alterna-
tively that CHIP inhibits chaperone-mediated protein refolding
of eNOS in vivo and instead diverts it to an insoluble and
inactive state, perhaps through deviations in trafficking that
are known to be required for eNOS activity (1, 2). To test this
hypothesis, transfected COS cells were fractionated into mem-
brane (high speed pellet), soluble, and insoluble (low speed
pellet) fractions, and eNOS protein levels in each fraction were
measured by Western blotting (Fig. 7A). In cells transfected
with eNOS, eNOS was found primarily in the high speed pellet
(fifth lane) relative to the low speed pellet (second lane) and
soluble fraction (eighth lane), consistent with the known tight
FIG. 5. CHIP does not increase eNOS ubiquitylation. A, in vitro ubiquitylation reactions were performed with purified proteins. Purified
ubiquitin, E1, the E2 UBCH5a, and eNOS were present in each reaction. In some reactions, Hsp70, Hdj1, or Hdj2 was included as indicated.
Following SDS-PAGE, blots were probed with anti-eNOS and anti-Hsp70 antibodies. B, in vitro ubiquitin conjugations were performed with in vitro
transcribed and translated 35S-labeled eNOS. 35S-Labeled eNOS was synthesized in reticulocyte lysate, followed by immunoprecipitation with
anti-eNOS antibody; and ubiquitin conjugation was performed with 35S-labeled eNOS, purified E1, or the E2 UBCH5a with or without CHIP.
Reactions were resolved by SDS-PAGE, followed by autoradiography. C, COS-7 cells were transiently transfected with eNOS, His-tagged ubiquitin
(Ub), or hemagglutinin-tagged ubiquitin (as a control) with or without CHIP or pretreatment with 2 M GA for 16 h as indicated. Two days after
transfection, cells were incubated with 2.5 M MG132 for 2.5 h and harvested with a denaturing buffer. His-tagged ubiquitylated forms of eNOS
were precipitated with Ni-NTA-agarose, resolved by SDS-PAGE, and detected with anti-eNOS antibody (upper panel). The same blot was stripped
and reprobed with anti-ubiquitin antibody (lower panel). NS, nonspecific.
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membrane association of this protein. Cotransfection of eNOS
with CHIP resulted in the redistribution of eNOS from mem-
brane and soluble pools to the insoluble pool (note the increase
in eNOS levels in the third lane and the decrease in the sixth
and ninth lanes in CHIP-transfected cells). The effects of CHIP
were specific, as the cellular distribution of endogenous Hsp70
and Hsp90 was not changed by CHIP (Fig. 7A). In addition, the
cellular localization of neither iNOS nor nNOS was modified by
CHIP; CHIP decreased iNOS and increased nNOS protein lev-
els in all three fractions, consistent with its overall effects on
these NOS isoforms (Fig. 7B). Despite the ability of CHIP to
direct eNOS into a detergent-insoluble fraction, eNOS activity
in this fraction was not increased; in fact, a decrease in the
apparent specific activity was observed (Fig. 7C), thus indicat-
ing that CHIP caused accumulation of inactive eNOS in the
detergent-insoluble fraction. Interestingly, we also noted that
the cellular localizations of Hsp70 and Hsp90 were different.
Hsp90 was limited to membrane and soluble pools, whereas
Hsp70 was present in all three fractions. (The differential
cellular localization of Hsp90 and Hsp70 may correlate with
their different cellular functions.) The deficiency of Hsp90 in
the detergent-insoluble fraction where eNOS accumulated sug-
gests that the interaction between Hsp90 and eNOS was dis-
rupted by CHIP.
CHIP Disrupts Golgi Trafficking of eNOS—To gain more
insight into the effects of CHIP on eNOS, we examined the
consequences of altering CHIP expression on endogenous
eNOS localization in bovine aortic endothelial cells. As ex-
pected, a major fraction of eNOS (green filter, Fig. 8, upper row)
co-localized with GM130 (red filter), a resident protein of the
Golgi apparatus, in the perinuclear region (merge is yellow).
Infection of cells with an adenovirus expressing red fluorescent
protein (middle row, showing red fluorescent protein-express-
ing cells) did not influence the distribution of either eNOS
(green filter, left panel) or GM130 (green filter, right panel).
However, in cells infected with an adenovirus expressing CHIP
(lower row), eNOS was redistributed from the perinuclear lo-
cation to discrete foci within the cytoplasm (left panel; eNOS is
green, and CHIP is red). Remarkably, the peripheral mem-
FIG. 6. Proteasome inhibitors do not block the effects of CHIP
on eNOS expression. A, COS-7 cells were transfected with eNOS with
or without CHIP and incubated with a proteasome inhibitor (20 M
lactacystin (LC), MG132, or proteasome inhibitor I (PI-I)) or vehicle
(dimethyl sulfoxide (DMSO)) for 2.5 h. B, alternatively, transfected cells
were incubated with MG132 under different conditions as indicated.
Detergent-soluble fractions of lysates were subjected to Western blot-
ting for eNOS, ubiquitin (Ub), and -actin. O/N, overnight.
FIG. 7. Accumulation of inactive detergent-resistant eNOS by
CHIP. COS cells were transfected with eNOS (A) or with nNOS or
iNOS (B) with or without CHIP. Lysates were fractionated as described
under “Experimental Procedures” and resolved by SDS-PAGE. Expres-
sion of NOS in each fraction was measured with the corresponding
anti-NOS antibodies (A, upper panel; and B). The same membrane
blotted for eNOS was reprobed with anti-Hsp90, anti-Hsp70, anti--
actin, and anti-CHIP antibodies (A). In C, COS cells were transiently
transfected as indicated. eNOS protein levels and activity in the deter-
gent-insoluble fractions of lysates were determined by Western blotting
and NOS activity assays, respectively. Data of the eNOS activity assay
are means  S.E. (n  4).
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brane Golgi protein GM130 was similarly redistributed (middle
panel; GM130 is green, and CHIP is red), and eNOS and
GM130 merged in the cytoplasm (right panel; eNOS is green,
and CHIP is red, with yellow reflecting the merged images).
These results indicate that CHIP impairs the Golgi targeting of
eNOS, which accounts for its redistribution in an insoluble
fraction and its lower specific activity. In addition, these obser-
vations suggest that the chaperone system may play a gener-
alized and unanticipated role in maintenance of Golgi integrity
and the trafficking of peripheral membrane proteins.
Deficiency of CHIP in Mouse Lung Endothelial Cells In-
creases Membrane-bound eNOS and Enhances eNOS Activity—
To firmly establish the importance of the observations of CHIP-
dependent eNOS regulation, we isolated lung endothelial cells
from adult CHIP/ mice (created by homologous recombina-
tion of embryonic stem cells)2 and similar cells from wild-type
littermates to determine eNOS localization and activity. In
CHIP/ cells, increased levels of eNOS were found in the
soluble and membrane-associated (high speed pellet) fractions,
and slightly lower levels were present in the insoluble (low
speed pellet) fraction (Fig. 9A). Consistent with this observa-
tion of increased translocation of eNOS to the membrane com-
partment in the absence of CHIP, we found that both basal and
vascular endothelial growth factor-induced eNOS activities
were increased by 2-fold in CHIP/ endothelial cells (Fig.
9B). A 2-fold increase in eNOS activity in CHIP/ endothelial
cells is likely to exert a profound physiological effect on func-
tion because the dose-response relationship to NO in intact
blood vessels is very steep, with small changes in NO levels
exerting great changes on vasomotion (34). These observations
provide further support for a model in which CHIP regulates
eNOS partitioning under physiological conditions and indicate
that eNOS is more efficiently translocated to the membrane
compartment, where it is maximally active, in the absence of
CHIP. Additionally, because the proper subcellular localization
of eNOS is critical for activation by mechanical forces and
growth factors (6, 35) and subsequent eNOS phosphorylation
(36), the levels or activity of CHIP may exert an unappreciated
control mechanism for the partitioning/trafficking of eNOS to
the Golgi and plasma membrane.
DISCUSSION
Previous studies have shown that CHIP is a U-box-depend-
ent E3 ligase that interacts with both Hsp70 and Hsp90 and
promotes ubiquitylation of some chaperone substrates in a
chaperone-dependent fashion (15, 16, 18, 19). We found that
inhibition of Hsp90 function by GA, a specific Hsp90 inhibitor,
increases ubiquitylation of another Hsp90 client protein,
eNOS. These results indicate the presence of Hsp90-mediated
pathways that regulate eNOS stability; and therefore, it is
reasonable to speculate that the Hsp90-binding ubiquitin li-
gase CHIP might be involved in the regulation of eNOS degra-
dation. To our surprise, although we observed a decrease in
eNOS protein levels by CHIP, we demonstrated through sev-
eral lines of evidence, contrary to our expectation, that this
phenomenon is not due to increasing ubiquitin-mediated deg-
FIG. 8. Displacement of eNOS from the Golgi by CHIP in endothelial cells. In the upper row, bovine aortic endothelial cells were fixed
and immunolabeled with an antibody that recognizes eNOS (fluorescein isothiocyanate-labeled secondary antibody) or GM130 (rhodamine-labeled
secondary antibody), and the merged image is shown. The merge of the two colors to yellow and arrows depict co-localization of eNOS and GM130.
In the middle row, bovine aortic endothelial cells were infected with an adenovirus-expressing red fluorescent protein (Ad-RFP) and labeled for
eNOS (left panel) or GM130 (right panel) decorated with fluorescein isothiocyanate-labeled secondary antibody. Arrows depict intact perinuclear
eNOS and GM130 in the cells infected with an adenovirus-expressing red fluorescent protein (red). In the lower row, bovine aortic endothelial cells
were infected with an adenovirus expressing CHIP, and eNOS/CHIP, GM130/CHIP, and eNOS/GM130 co-localization was examined. The presence
of CHIP caused the redistribution of eNOS (left panel) and GM130 (middle panel). The right panel demonstrates the merged image showing
co-labeling for eNOS (fluorescein isothiocyanate) and GM130 (rhodamine). Data are representative of at least seven individual experiments.
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radation of eNOS. CHIP does not elicit eNOS ubiquitylation,
but rather causes eNOS to redistribute into an inactive deter-
gent-insoluble pool by preventing eNOS targeting or by displac-
ing eNOS from the Golgi.
It is now well established that molecular chaperones play
essential roles in protein quality control not only by aiding
protein folding and refolding, but also by directly contributing
to protein degradation when proteins are no longer needed or
permanently damaged (37). Disruption of Hsp90 function by
GA induces ubiquitylation and proteasome-dependent degra-
dation of several Hsp90 client proteins, including the steroid
hormone GR, the plasma membrane chloride channel CFTR
(38), the serine/threonine kinase Raf-1 (39), the receptor tyro-
sine kinase ErbB-2 (40), and the basic helix-loop-helix/PAS
family transcription factor hypoxia-inducible factor-1 (41), in-
dicating the involvement of molecular chaperones in their ubiq-
uitin-mediated degradation. These studies also imply potential
roles for CHIP, the chaperone-dependent ubiquitin ligase, in
these events. Interaction of CHIP with molecular chaperones
appears to enable CHIP to gain access to a broad spectrum of
chaperone-bound substrates for subsequent ubiquitylation and
targeting to the proteasome for degradation. This raises the
question of whether CHIP ubiquitylates substrates captured by
chaperones in a general manner, or if this is otherwise a selec-
tive process. CHIP promotes polyubiquitin chain formation on
some of these Hsp90 clients, such as GR (15), CFTR (16), Raf-1
(18), and ErbB-2 (17), which leads to their subsequent degra-
dation by the proteasome. In contrast, eNOS is not a target for
the ubiquitin ligase activity of CHIP. Taken together with our
data, these results suggest that CHIP does not generally ubiq-
uitylate all substrates presented by the molecular chaperones.
Given the limited substrate set presently known, it is difficult
to speculate on common structural features that characterize
CHIP substrates. Nevertheless, the present data showing the
selectivity of CHIP for misfolded, abnormal, and/or mutant
proteins (16, 17, 20) indicate that the conformation and folding
state of these proteins may serve as recognition signals for
CHIP. Given this likelihood, it is of interest to note that the
allosteric activation (3) and scaffold effect (8) of Hsp90 on eNOS
suggest that it is the eNOS dimer that interacts with Hsp90.
This conformation of Hsp90-bound eNOS is relatively stable
and thus might not be recognized by the E3 ligase CHIP for
ubiquitylation. Such a model would explain the ubiquitylation-
independent effects of CHIP observed in our studies. In addi-
tion, the observation that the Hsp90 inhibitor GA induced the
ubiquitylation of eNOS (Fig. 5C), whereas CHIP did not, ar-
gues strongly in favor of the existence of another chaperone-
associated ubiquitin ligase in addition to CHIP.
Our observations that CHIP modulated eNOS partitioning
within cells are, to our knowledge, a novel co-chaperone-de-
pendent mechanism through which eNOS may be regulated.
That Hsp90 was not present in the detergent-insoluble fraction
is informative regarding the mechanism through which CHIP
acts. It is possible that CHIP, via its ability to interact with and
to modify the function of the molecular chaperone Hsp90,
causes a conformational change in Hsp90 that dissociates
plasma membrane-associated eNOS from Hsp90 (3) and that
Hsp90-free eNOS becomes unstable, inactive, and perhaps
prone to aggregation. Alternatively, CHIP may interfere with
chaperone-mediated solubility of eNOS during biosynthesis
from its cytoplasmic state (i.e. during co-translational myris-
toylation and post-translational palmitoylation) to its final des-
tination on the Golgi and plasma membrane (1, 2, 36). It is even
possible that CHIP may interact with eNOS after eNOS has
been inserted into the Golgi because eNOS is targeted to the
cytoplasmic face of the Golgi and is therefore accessible to
CHIP at all times during its biosynthesis and activation (6).
This latter observation is particularly notable, as increased
levels of CHIP appear to elicit a global disassembly of the Golgi
complex, based on the re-localization of GM130, a well charac-
terized peripheral membrane Golgi marker. This effect does
not seem to be due to a general inhibition of protein processing
pathways because similar increased levels of CHIP do not
generally alter endoplasmic reticulum structure or processing
of the T-cell receptor, which requires the integrity of the endo-
plasmic reticulum.3 In addition, the folding of some proteins is
actually enhanced when CHIP levels are elevated (42). To date,
there are few indications of a role for molecular chaperones in
Golgi function or integrity. It is possible that CHIP participates
in the regulation of Golgi function, either directly or (more
likely) through interactions with chaperones, although this
model will need to be tested in further studies.
In any event, the contrast between the effects of CHIP on
eNOS and nNOS is striking. Although eNOS and nNOS iso-
forms share very similar primary structures, functional do-
mains, and biochemical features, CHIP exhibits totally oppo-
site effects on them. The significance and mechanisms by which
CHIP increases nNOS protein expression are unknown at pres-
ent. The primary structure of nNOS is very similar to that of
eNOS except for a distinct N-terminal 220-amino acid leader
sequence (43). The nNOS leader sequence contains a PDZ
domain-binding motif that interacts with several proteins that
may target the enzyme to signal transduction hot spots within
cells. It also contains a binding site for a highly conserved and
widely expressed protein, PIN (protein inhibitor of NO syn-
thases), which, when bound to nNOS, appears to destabilize its
dimeric structure (44). nNOS is an Hsp90 substrate as well.
Disruption of Hsp90 by GA increases nNOS turnover (45). The
3 D. Cyr, unpublished data.
FIG. 9. eNOS localization and activity in mouse lung endothe-
lial cells. A, cell lysates from CHIP/ and CHIP/ murine lung
endothelial cells were separated into the indicated fractions and probed
for eNOS, CHIP, and -actin by Western blotting. B, NOS activity was
determined in total cell lysates from CHIP/ and CHIP/ murine
lung endothelial cells before and after stimulation with vascular endo-
thelial growth factor (VEGF; 20 ng/ml). Data are expressed as means 
S.E. (n  6). *, p  0.05 compared with basal levels from CHIP/ cells;
**, p  0.05 compared with vascular endothelial growth factor-inducible
levels from CHIP/ cells.
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effect of CHIP on nNOS is different from that of GA, implying
an Hsp90-independent effect. Therefore, it is reasonable to
postulate that with respect to its effects on steady-state nNOS
levels, the direct target of CHIP might be some protein other
than nNOS itself, and the most likely candidates lie in unique
nNOS-interacting proteins that affect nNOS protein stability.
Structurally, both the TPR and U-box domains of CHIP are
required for its effects on eNOS distribution (Fig. 3). That the
TPR domain is required is not surprising because this domain
is required for the interaction of CHIP with Hsp90 (15). The
requirement of the U-box in this process is less clear, as CHIP
does not induce ubiquitylation of eNOS. It is possible that the
ubiquitin ligase activity is required for ubiquitylation of a pro-
tein or proteins other than eNOS and that this contributes in
part to the redistribution of eNOS. Alternatively, it is possible
that the U-box has functions (in addition to its ubiquitin ligase
activity) that participate in the regulation of eNOS by CHIP.
Further studies will be required to distinguish between these
possibilities.
Recently, two additional proteins that modulate eNOS dis-
tribution have been identified. NOSTRIN (eNOS traffic in-
ducer) and NOSIP (eNOS-interacting protein) were both iden-
tified by their interactions with the eNOS oxygenase domain in
yeast two-hybrid screens (46, 47). Both of these proteins appear
to affect eNOS localization by redistribution from the plasma
membrane into insoluble cytoplasmic compartments in overex-
pression studies similar to those performed here. The activities
of NOSTRIN and NOSIP stand in contrast to that of CHIP,
which diverts eNOS from its normal trafficking pathway at the
Golgi or pre-Golgi level. Whether the final destination of eNOS
is to a similar compartment after diversion by each of these
proteins is not clear, although this is a distinct possibility. In
any event, these separate studies indicate the existence of
multiple mechanisms for diversion of eNOS from its “normal”
trafficking pathway and provide further evidence for the pre-
cise regulation of intracellular localization and activity of
eNOS.
Having previously identified CHIP as an E3 ligase for the
chaperone substrates GR and CFTR (15, 16, 19), our studies
demonstrate that CHIP modulates the chaperone substrate
eNOS in a manner independent of its ubiquitin ligase activity.
In these studies, we have identified a novel co-chaperone-de-
pendent mechanism of eNOS regulation. CHIP inactivates
eNOS by uncoupling its interaction with Hsp90 and by parti-
tioning eNOS from the normal Golgi transit pool. Reduction in
the expression or activity of eNOS is a hallmark of cardiovas-
cular diseases such as hypertension, diabetes, heart failure,
and arteriosclerosis. Thus, negative regulation of eNOS by
CHIP suggests that it might serve as a new target for inter-
vention in the treatment of cardiovascular disease. In addition,
we have shown for the first time that eNOS can be regulated
through the ubiquitin-proteasome pathway under certain cir-
cumstances (i.e. chaperone dysfunction induced by GA). Our
studies indicate the potential existence of novel chaperone-de-
pendent ubiquitin ligases for eNOS and provide new directions
for future research.
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